Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CYTR $2.50 0.3700 +17.37%
SRNE $5.52 0.6300 +12.88%
ATRA $15.41 1.4000 +9.99%
BPMC $16.26 1.4200 +9.57%
CRIS $1.44 0.1200 +9.09%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

PVCT $0.43 -0.0298 -6.48%
CBMG $16.43 -0.4600 -2.72%
APRI $1.14 -0.0300 -2.56%
CERU $1.95 -0.0400 -2.01%
RNN $0.36 -0.0069 -1.87%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda

(StreetInsider) Feb 4, 2016 - Seattle Genetics, Inc., today announced that it will receive a one-time $20 million milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda).
read article 

FDA Approves Merck's Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)

(Merck) Feb 4, 2016 - First and only intravenous NK1 receptor antagonist approved in the U.S. for use in MEC.
read corporate press release 

Meditation Eases Pain, Anxiety and Fatigue During Breast Cancer Biopsy

(Duke Medicine) Feb 4, 2016 - Meditation eases anxiety, fatigue and pain for women undergoing breast cancer biopsies, according to researchers at the Duke Cancer Institute. They also found that music is effective, but to a lesser extent.
read press release 

Obesity Impact on Generational Cancer Risk 'Needs Study’

(Medscape Medical News) Feb 4, 2016 - More research is needed to unravel the complex relationship between obesity and cancer risk, including the transmission of cancer risk across generations via maternal obesity, argue two experts in a review of the current scientific evidence.
read article (free registration required) 

Investigating Surgery for Women at High Risk of Breast and Ovarian Cancer

(Mayo Clinic) Feb 3, 2016 - In a review article published in the Feb. 4 issue of the New England Journal of Medicine, a pair of Mayo Clinic Cancer Center researchers provide an in-depth look at the issues associated with the care of women in families with hereditary breast and ovarian cancer syndrome who have not yet developed cancer themselves.
read article 

Here's Why ImmunoGen's CEO Is Psyched for Combo Tests With Keytruda

(Boston Business Journal/BioFlash blog) Feb 4, 2016 - ImmunoGen says that in coming months it plans to test its experimental cancer drug in combination with Merck’s drug, Keytruda, after mouse trials done internally at the company — confirmed by academic studies — show the two drugs may multiply each others' effects.
read article 

ASCO Names Advance of the Year: Cancer Immunotherapy

(ASCO) Feb 4, 2016 - At a Capitol Hill briefing today, the American Society of Clinical Oncology (ASCO) announced immunotherapy as the top cancer advance of the year. Recent breakthroughs in immunotherapy – along with almost 60 other important cancer research advances – are described in ASCO’s just-released report, Clinical Cancer Advances 2016: ASCO's Annual Report on Progress Against Cancer.
read press release 

FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)

(Merck) Feb 4, 2016 - First and only intravenous NK1 receptor antagonist approved in the U.S. for use in MEC.
read corporate press release 

ImmunoGen and Merck Establish Collaboration for Clinical Evaluation of Mirvetuximab Soravtansine in Combination with Keytruda(R) (pembrolizumab) for the Treatment of Ovarian Cancer

(ImmunoGen) Feb 4, 2016 - ImmunoGen's mirvetuximab soravtansine folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC) to be assessed in combination with Merck's anti-PD-1 therapy.
read corporate press release 

Pfizer, J&J, Merck Evaluating Technologies For Zika Vaccine

(Reuters) Feb 3, 2016 - Pfizer Inc, Johnson and Johnson and Merck & Co Inc said they were evaluating their technologies or existing vaccines for their potential to combat Zika, a rapidly spreading mosquito-borne disease linked to birth defects.
read article 

Cancer Treatment Development To Be Speeded Up By New London Research Hub

(The Guardian/Press Association [UK]) Feb 3, 2016 - New cancer research campus to bring together 10,000 scientists, clinical and support staff and hopes to deliver at least two new drugs every five years.
read article 

Zika Infection Transmitted by Sex Reported in Texas

(New York Times) Feb 2, 2016 - Officials in Dallas reported that a patient with Zika virus was infected after having sex with an ill individual who had returned from a country where Zika was circulating.
read article 

The Startup Tracking ‘Valuable’ Doctors for Big Pharma

(BloombergBusinessweek) Feb 3, 2016 - Zephyr Health says it can determine the value of a doctor’s prescription pad.
read article 

Study by Leading Loyola Thoracic Surgeon Suggests Improvements In How Mesothelioma Is Measured

(Loyola Medicine) Feb 3, 2016 - A new study suggests that significant improvements could be made in the scoring system physicians use to estimate the stage (severity) of mesothelioma, an aggressive and deadly cancer.
read press release 

Congress: Drugmakers Planned Price Increases To Boost Profits

(Detroit Free Press/Associated Press) Feb 2, 2015 - Two drugmakers have made a practice of buying and then dramatically hiking the prices of low-cost drugs given to patients with life-threatening conditions including heart disease, AIDS and cancer, according to excerpts from thousands of documents released by federal lawmakers.
read article 

Sen. Ted Cruz Wants To Change The Way The FDA Approves Drugs

(Forbes) Feb 3, 2016 - Giving Congress the right to overrule FDA approval decisions would make the process more political than scientific.
read article 

Penn Cancer Center Founder Richard "Buz" Cooper Dies

(The Daily Pennsylvanian) Feb 3, 2016 - Recently, the Penn community lost one of its finest members — a doctor, researcher, leader and teacher.
read article 

Government Missed Cancer Waiting Times Target, PM Admits

(The Guardian [UK]) Feb 3, 2016 - David Cameron has said the government needs to improve its performance on cancer waiting times, admitting it had missed a target for patients to be treated within 62 days of an urgent referral from a GP.
read article 

J&J's Talcum Powder Goes on Trial in Ovarian Cancer Lawsuits

(Bloomberg) Feb 2, 2016 - Johnson & Johnson, already facing lawsuits over products from surgical mesh to antipsychotic drugs, began trial Tuesday over claims the talcum powder it marketed to women gave some of them cancer.
read article 

First Patient Treated With LC Bead LUMI™ Radiopaque Embolic Bead Supported by Philips Live Image Guidance

(TheStreet) Feb 3, 2016 - BTG plc, a global specialist healthcare company, and Royal Philips, announced today a significant milestone in their collaboration with the treatment of the first liver cancer patient with LC Bead LUMI™ in conjunction with Philips Live Image Guidance, targeting a hypervascular tumor with the goal to block blood flow to achieve tumor necrosis.
read article 

Morphotek Announces Collaboration with Mayo Clinic to Apply Its Folate Receptor Alpha Diagnostic Assays in a Phase II Clinical Trial in Triple-Negative Breast Cancer

(Morningstar) Feb 3, 2016 - Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it is collaborating with researchers Keith L. Knutson, Ph.D. in the Department of Immunology and Edith A. Perez, M.D. in the Department of Hematology and Oncology at Mayo Clinic in Jacksonville, Florida in a clinical study in patients with folate receptor alpha (FRA) positive, triple-negative breast cancer (TNBC).
read article 

Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer® Antibody-Drug Conjugates and XMT-1522

(Takeda) Feb 3, 2016 - Mersana Therapeutics and Takeda Pharmaceutical Company Limited today announced that they have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the United States and Canada.
read corporate press release 

OXiGENE Says FDA Approved Protocol for Phase 2/3 Study of CA4P for Treatment of Platinum-Resistant Ovarian Cancer

(StreetInsider) Feb 3, 2016 - FOCUS will test whether CA4P, the company’s lead investigational drug, improves progression-free survival (PFS) when combined with bevacizumab (Avastin®) and chemotherapy.
read article 

FDA Grants TapImmune Fast Track Designation For Lead Vaccine In Ovarian Cancer

(NASDAQ/ Feb 3, 2016 - TapImmune Inc., a clinical-stage immuno-oncology company, said that the U.S. Food & Drug Administration or FDA has granted Fast Track Designation for its cancer vaccine TPIV 200 in the treatment of ovarian cancer.
read article 

Trillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47

(CNNMoney) Feb 3, 2016 - Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has initiated dosing in its Phase 1 clinical trial of TTI-621 (SIRPaFc), a novel checkpoint inhibitor of the innate immune system, in relapsed or refractory hematologic malignancies.
read article